Overview

Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Status:
Recruiting
Trial end date:
2025-10-19
Target enrollment:
Participant gender:
Summary
The rationale for this study is to investigate whether in psoriatic arthritis (PsA) patients in stable remission a reduction or complete discontinuation of immunosuppressive therapy can be achieved in a treat-to-target approach while maintaining in remission. Due to the lack of reliable data that answers the question of how to safely reduce medication in which patients, this study will test a pragmatic treatment algorithm that can be applied in clinical practice and that offers a gradual reduction with escape strategies in order to facilitate the maintenance of remission.
Phase:
Phase 3
Details
Lead Sponsor:
University of Erlangen-Nürnberg Medical School
Treatments:
Abatacept
Adalimumab
Apremilast
Certolizumab Pegol
Etanercept
Golimumab
Infliximab
Ixekizumab
Leflunomide
Methotrexate
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Sulfasalazine
Tofacitinib
Ustekinumab